FluoGuide A/S (STO: FLUO)

Market Cap	561.83M
Revenue (ttm)	1.76M
Net Income (ttm)	-49.46M
Shares Out	13.62M
EPS (ttm)	-3.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,422
Open	39.10
Previous Close	39.15
Day's Range	38.55 - 46.35
52-Week Range	31.85 - 80.00
Beta	1.08
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 28, 2024

About FluoGuide

FluoGuide A/S, a clinical stage biotechnology company, focused on developing drugs for surgical outcomes by making cancer fluorescent in Denmark. Its lead product candidate is FG001, which is in Phase IIa and IIb for the treatment of high-grade glioma; Phase II clinical trial for the treatment of lung cancer, and head and neck cancer. The company also develops FG002, which is in preclinical stage that allows surgeons to differentiate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology. It has an agreeme...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 8
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: FLUO

Financial Performance

In 2023, FluoGuide's revenue was 423,000, a decrease of -93.50% compared to the previous year's 6.51 million. Losses were -38.38 million, 40.4% more than in 2022.

Financial numbers in DKK